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Open Source Synthetic Biology: Problems and Solutions
Ethan R. Fitzpatrick*

I. Introduction
In May 2010, the J. Craig Venter Institute announced the creation of a simple bacterial
cell entirely controlled by a chemically synthesized genome.1 The scientists started with the
digital information of the organism’s genomic DNA sequence and chemically synthesized one
nucleotide at a time, the full 1.08 million base pairs that made up the organisms genome.2 The
synthetic genome was then inserted into a host bacterium that had its native DNA removed.3
The resulting man-made bacterium was able to replicate itself using only the synthetic genome.4
Advances in the ability to synthesize genome-length strands of DNA have coincided with a
growing understanding of the functions of individual genes and gene networks.5 With the
available knowledge of how whole genomes function and the technical capability of synthesizing
whole genomes, it will be possible to digitally design novel organisms to perform some desired
function and then manifest that synthetic organism in the real world.6 Creation of the first
synthetic organism provided “a proof of principle for producing cells based on computerdesigned genome sequences. DNA sequencing of a cellular genome allows storage of the
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genetic instructions for life as a digital file.”7 “The approach we have developed should be
applicable to the synthesis and transplantation of more novel genomes as genome design
processes.”8
This ultimate goal of designing novel synthetic organisms using the technology of
synthetic biology sounds like pure science fiction, but it is entirely possible and would have an
enormous impact on biotechnology and medicine. Synthetic organisms might be designed to
create new sources of food, fuel, and medicine that current technology is not capable of
producing. Additionally, these benefits will arrive with incredible speed, efficiency, and cost
effectiveness. Designing wholly novel synthetic organisms is still on the horizon, however, and
presently scientists are left with a combination of older methods to innovate in the field of
biotechnology, or more recently, the emerging technology of synthetic biology in its earliest
phase. In order to make the possibilities of synthetic biology a reality in the least amount of
time, one organization—the BioBricks Foundation—is attempting to protect this emerging field
from the potential stifling effects of DNA-patents by establishing an open source movement.9
The hope is that an open-source synthetic biology commons would encourage innovation in
ways similar to the wildly successful open source software movement.10 Towards that end, a
similar open-source approach to synthetic biology might be useful.11 The world of synthetic
biology, however, poses unique problems to the establishment of an open source movement.
These problems include incentivizing entities to participate, maintaining openness once it is
established, and creating useable biomedical products.
7
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Part II of this Comment provides an overview of the technology of synthetic biology and
explains why it is important. Part III introduces the current movement towards open source
synthetic biology, as established by the BioBricks Foundation, and Part IV describes the past
strategies used to establish and maintain other analogous open-source biotechnology movements.
Three specific strategies are discussed: a copyright approach, a contract-based approach, and a
patent-based approach to establish and maintain a commons. Part V then assesses whether these
approaches to maintaining a synthetic biology commons are possible, and if so, what problems
might be unique to synthetic biology. Part VI then proposes a wholly novel strategy to advance
the progress of synthetic biology.

This strategy uses an open-source/property-right hybrid

approach, under the auspices of a standard setting organization, in order to overcome problems
that cannot be addressed under the three previously described strategies. The Comment then
concludes.

II. Synthetic Biology: What is it and Why is it?
A. Recombinant DNA technology laid the foundation for genetic engineering.
Deoxyribonucleic acid (DNA) is the molecule which encodes the instructions for life.12
The DNA language uses four nucleotides—adenine, thymine, cytosine, and guanine—organized
in specific sequences to compose the genes responsible for heritable traits.13 The DNA sequence
of an organism gets copied with an extremely high fidelity, averaging only one nucleotide error
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BRUCE ALBERTS ET AL., MOLECULAR BIOLOGY OF THE CELL 193 (4th ed. 2002).
Id. at 194.
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for every billion nucleotides copied.14

This DNA sequence is passed on to offspring,

transmitting genetic information from generation to generation.15
Scientists have been tinkering with DNA since 1972, when Paul Berg, Stanley Cohen,
and Hubert Boyer, discovered a way to cut and paste pieces of DNA together.16 This was
followed by many further advances in manipulating sequences of DNA, such as the invention of
the “polymerase chain reaction” (used to amplify pieces of DNA), rapid sequencing technology,
and targeted gene replacement.17 Before the development of these technologies, the sheer size
and chemical-repetitiveness of DNA made it one of the most difficult molecules to study and
manipulate.18 The advent of the above methods, however, now makes DNA one of the easiest
molecules to manipulate.19 Presently, the technology has reached a level of such sophistication
that scientists routinely recombine the DNA sequences within a species (or even between
species), resulting in novel DNA sequences that do not exist in nature.20 This “recombinant
DNA technology” (rDNA technology) has had numerous applications as far reaching as
medicine, research, and agriculture.21 Despite these advances, however, scientists have been
limited by rDNA technology.22

Generally, rDNA techniques involve manipulating a small
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number of genes and each modification involves a very time consuming procedure.23 This
limitation, together with a very superficial understanding of how genes work alongside one
another, has resulted in most scientific advances using rDNA technology involving the
engineering of a single gene.24 For example, recombinant human insulin, which has almost
entirely replaced insulin derived from animal sources,25 is synthesized by expressing a single
human insulin gene in the bacteria E. Coli.26 In the specific case of human insulin production,
manipulation of a single gene is sufficient to achieve the desired result; creating an alternative
source of insulin for people with diabetes.27 In some situations, however, manipulating single
genes is not sufficient and in those cases the emerging technology of synthetic biology is
allowing scientists to move beyond the limitations imposed by recombinant DNA techniques.

B. Defining the New Technology of Synthetic Biology
Defining synthetic biology is not easy. There is no bright line that distinguishes the older
rDNA technology from the new synthetic biology. 28 The term has arisen in light of advanced
techniques for chemically synthesizing sequences of DNA, along with a growing understanding
of how multiple genes work in groups to form “gene networks” or “gene circuits.”29

Thus, it is

not surprising that the term means something different depending on one’s technical background.
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See e.g., Bruce A. Roe et al., Protocols for Recombinant DNA Isolation, Cloning, and Sequencing,
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Drew Endy, one of the pioneers of synthetic biology, states that for the biologist, the term means
“the ability to design and construct synthetic biological system [to] provide a direct and
compelling method for testing our current understanding . . . .”30 For the chemist, synthetic
biology “is an extension of synthetic chemistry[:] the ability to create novel molecules and
molecular systems [to allow] the development of useful diagnostic assays and drugs, expansion
of genetically encoded functions, [and] study of the origins of life . . . .”31 For the group of
people Endy terms “re-writers,” the term means that “the genomes encoding natural biological
systems can be ‘re-written,’ producing engineered surrogates that might usefully supplant some
natural biological systems.”32 And finally, for engineers, synthetic biology is an attempt “to
combine a broad expansion of biotechnology applications with . . . an emphasis on the
development of foundational technologies that make the design and construction of engineered
biological systems easier.”33
For the purposes of this Comment, the technology of synthetic biology is summarized as
follows: Advances in the ability to chemically synthesize sequences of DNA, plus a growing
understanding of how genes function singularly and in groups, allowing scientists to treat genes
as biological parts that they can use to engineer a living organism—much like an engineer would
use various parts to build a car. This Comment adopts this definition of synthetic biology
because the technological capability of designing standardized biological parts is necessary for
the establishment of open-source synthetic biology.34 The definition is largely drawn from
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Endy, supra note 28.
Id.
32
Id.
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Id.
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See David W. Opderbeck, The Penguin’s Genome, or Coase and Open Source Biotechnology, 18 HARV. J.L. &
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Endy’s engineering perspective of synthetic biology in order to stress the importance of
composable biological parts that individuals can design and then contribute to a synthetic
biology commons.

Also, this definition emphasizes that the difficulty or ease with which

scientists can create biological parts will be an important factor in the success or failure of a
synthetic biology commons.35

C. Faster, Easier Genetic Engineering via Synthetic Biology
One of the underlying goals of synthetic biology is to make genetic engineering faster
and easier.36 This goal can only be reached if standardized tools and methods are established
that make genes and gene networks function predictably and reliably. Unfortunately, current
rDNA techniques largely lack any kind of standardization, which severely reduces the pace of
technological innovation.37 An analogy might be building a car from scratch—starting with
screws and a screw driver, finishing with a fully functional car. An engineer with established
tools and parts can build a car from scratch with little difficulty because the function of each part
is known and standards are in place for parts to work together. But imagine the challenge of
building a car from scratch not knowing how each part works or whether individual parts can
work together. Without standard parts and tools, the builder would work by trial and error,
small. With this in mind, I emphasize the development of discrete biological parts in my definition of synthetic
biology.
35
See id. Professor Opderbeck points out that rDNA technology poses some technical problems with respect to
component “layers” in the context of open source biotechnology. For example, manipulating DNA requires
specialized equipment and expertise. Advances in synthetic biology, however, might significantly lower this open
source barrier. Specifically, advances in DNA synthesis methods have the potential to make manipulating DNA
sequences easy, fast, cheap, and without formal training. Standardization of biological parts may also fulfill the
need for a common biotechnology platform. Professor Opderbeck also notes that to establish open source
biotechnology, there must exist social-psychological rewards and a community of contributors with authoritative
voices. While these two factors are outside the scope of this Comment, the BioBrick Foundation could arguably be
in the initial stages of fulfilling these needs.
36
Reshma P. Shetty, Drew Endy, & Thomas F. Knight, Engneering BioBrick Vectors from BioBrick Parts, 2
JOURNAL OF BIOLOGICAL ENGINEERING 1, 1 (2008), available at http://www.jbioleng.org/content/2/1/5
37
See Endy, supra note 28.
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resulting in a significantly longer time to completion. This problem is compounded in the
context of a living organism—biological systems are far more complex than a car, and every
biological part has the opportunity to interact with every other biological part. Presently, all
engineering of novel gene networks requires a significant amount of trial and error during
development. For this reason, without standardized biological parts, the pace of innovation will
be glacial.
To make this point, Endy uses the example of creating a biological oscillator.38 An
electrical engineer could create several working ring oscillators in under an hour.39 In contrast, it
took two of the world’s best biophysicists a year to make an analogous biological oscillator.40
The difference is that electrical engineers have standard parts available to them that work
predictably and reliably, while people working in the biological sciences do not.41 If synthetic
biological techniques are used to make molecular biology more like an engineering discipline, it
will rapidly increase the rate at which scientists create biotechnology-related products and
therapies.
One area that would benefit from an increase in the pace of progress is in the field of
medicine. Recently, scientists have taken a synthetic biology approach to engineer biological
systems as novel therapies in a pre-clinical setting.42 For example, scientists engineered a
bacteriophage (a virus that infects bacterium) that can destroy bacterial biofilms resistant to
antibiotics.43 Another example is a bacteria engineered to invade cancer cells in a solid tumor.44

38

Warren C. Ruder, Ting Lu, & James J. Collins, Synthetic Biology Moving into the Clinic, 333 SCIENCE 1248,
1249 (2011).
39
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A synthetic organism is even being developed to modify the “human microbiome,” the
endogenous ecosystem of bacteria found in all healthy people which is required for normal
physiology.45 Scientists are engineering the microbiome bacterium to live in the human gut with
the ability to prevent the secretion of toxins from cholera.46 Other bacteria have been engineered
to secrete various factors to treat diabetes or HIV.47 Scientists may even be able to engineer a
laboratory mosquito that is resistant to hosting malaria and that would be able to pass the
resistance trait into the natural population of mosquitoes.48
All of these advances were the result of manipulating genomes by removing and/or
adding various parts to alter biological pathways.49 These first few attempts at controlling the
behavior of an organism with synthetic biology techniques—by manipulating a relatively modest
number of genes—is useful for animal studies.50 But in order to be possible in human beings, it
“may be necessary to identify entirely new modules and components from endogenous networks
as well as to synthesize and characterize diverse component libraries.”51 In order to support
human application, the degree of control over the behavior of synthetic organisms will have to
increase dramatically.52 There is a strong motivation to advance the technology of synthetic
biology as fast as possible given the immense promise in the field of medicine. The quicker that
scientists make advances, the sooner they will develop wholly novel therapies to treat human
disease.

45

Id.
Id. at 1249.
47
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48
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50
Id.
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III. Advancing Genetic Engineering Through Open-Source Synthetic Biology
The benefits of synthetic biology’s engineering principles are clear: faster, easier, and
more novel solutions to the world’s biologically addressable problems.

But the question

remains: Once standard biological parts are created, how should they be used in order to foster
innovation? Currently, gene patents dominate the biotechnology landscape.53 Literally tens of
thousands of human genes are patented by various companies who solely own the patent rights to
use them.54 Many commentators have posited that these patent rights slow the pace of progress
dramatically.55 Emerging technologies are, by their very nature, especially vulnerable to broad
patents that suppress innovation.56 Some commentators fear that “foundational patents” (also
known as “upstream patents”), which are patents that cover an essential aspect of a technology
and are usually very broad in scope, will stifle the development of synthetic biology, along with
all of its potential benefits to mankind.57 This is because the technology that a foundational
patent covers is necessarily incorporated into any downstream research or resulting product. 58
One response addressing the potential threat of patents inhibiting synthetic biology
innovation is to establish a synthetic biology commons where standard biological parts are made
freely available to all.59 Once foundational biological parts are made publicly available in such a
commons, individual entities would not have the right to patent them. 60 Furthermore, some

53

See Sam Kean, The Human Genome (Patent) Project, 331 SCIENCE 530 (2011).
Id. at 531.
55
See Micheal A. Heller & Rebecca S. Eisenberg, Can Patents Deter Innovation? The Anticommons in Biomedical
Research, 280 SCIENCE 698 (1998) (patents over various biomedical technologies may result in an “anticommons”
where intellectual property rights result in underutilization of technology that hinders advancement).
56
Id.
57
See Heller & Eisenberg, supra note 55, at 698; Sapna Kumar and Arti Rai, Synthetic Biology: The Intellectual
Property Puzzle, 85 TEX. L. REV. 1745, 1757 (2007).
58
See Heller & Eisenberg supra note 55, at 698.
59
Joachim Henkel & Stephen M. Maurer, The Economics of Synthetic Biology, 3 MOLECULAR SYSTEMS BIOLOGY 1,
3–4 (2007), available at http://www.nature.com/msb/journal/v3/n1/full/msb4100161.html.
60
35 U.S.C. § 102(a)
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commentators have argued that this strategy has the added benefit of encouraging innovation.61
This “open-source” approach to synthetic biology is analogous to the open-source software
movement which was wildly successful and resulted in the creation of countless computer
applications including the Linux operating system.62
The following subsections examine what it means to be “open-source” and how those
open-source principles are currently applied to the emerging technology of synthetic biology.
One organization in particular, the BioBricks Foundation, has been established in an initial
attempt to launch an open-source community.63 Part III. A will describe what it means to be
“open-source,” and the terms used to maintain openness in the context of computer software.
Part III. B will discuss the open-source strategy of the BioBricks Foundation, and Part III. C will
consider the problems associated with maintaining openness.

A. Open Source
The term “open source” has become strongly associated with computer software code
that is made freely available for individual use and modification.64 The principles that opensource computer programmers established, however, are applicable to other technologies,
including synthetic biology. The Open Source Initiative (OSI), which uses the term in the
software context, defines “open source” as terms of distribution that comply with specific
criteria.65 The OSI uses ten different terms of distribution, all of them written with software

61

Andrew W. Torrance, Synthesizing Law For Synthetic Biology, 11 MINN. J. L. SCI. & TECH. 629, 650–51 (2010).
Id. at 654.
63
About the BioBricks Foundation, BIOBRICKS.ORG, http://biobricks.org/about-foundation/ (last visited Feb. 11,
2012).
64
Open Source Definition, OPENSOURCE.ORG, http://www.opensource.org/osd.html (last visited Feb. 11, 2012).
65
Id.
62
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development in mind.66 But each term can be applied to other technologies where non-rivalrous
information67 is being freely distributed, including the technology of synthetic biology. The
most important OSI requirements with respect to maintaining openness are: allowing free
redistribution, allowing derived works, and allowing a distribution of licenses.68

The free

redistribution term requires that a “license shall not restrict any party from selling or giving away
the software as a component of an aggregate software distribution containing programs from
several different sources. The license shall not require a royalty or other fee for such sale.”69
The derived-works term states that “the license must allow modifications and derived works, and
must allow them to be distributed under the same terms as the license of the original software.”70
And the distribution of license term states that “the rights attached to the program must apply to
all to whom the program is redistributed without the need for execution of an additional license
by those parties.”71 Importantly, software developers writing computer code have the intellectual
property rights—in copyright law—that are required to impose these terms on others who would
use their works.72 The BioBricks Foundation is a pioneering institution that is actively seeking
to establish an open source biotechnology community by applying open source principles to the
emerging field of synthetic biology.73

66

Id.
See Opderbeck, supra note 34, at 207–08. (“[I]nformation commons theorists hold that information is nonrivalrous because an infinite number of people can simultaneously think the same idea without diminishing the
idea’s content.”)
68
Open Source Definition, supra note 64.
69
Id.
70
Id.
71
Id.
72
17 U.S.C. § 101 (Literary works include words, numbers, or other indicia, regardless of the nature of its
embodiment).
73
The BioBricks Foundation works to ensure that the engineering of biology is conducted in an open and ethical
manner to benefit all people and the planet, BIOBRICKS.ORG, http://biobricks.org (last visited Feb. 11, 2012) (“We
are dedicated to advancing synthetic biology to benefit all people and the planet. To achieve this, we must make
engineering biology easier, safer, equitable, and more open. We do this in the following ways: by ensuring that the
67
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B. BioBricks Foundation
The BioBricks Foundation is an organization established to advance the field of synthetic
biology “by ensuring that the fundamental building blocks of synthetic biology are freely
available for open innovation.”74 Toward that end, the BioBricks Foundation has established the
first synthetic biology commons where various DNA “parts” are made freely available for public
use, applying open-source software principles.75
With the goal of openness in mind, the foundation has created User/Contributor
contracts—collectively titled “BioBricks Public Agreement”—to promote the use and innovation
of BioBricks parts.76 The terms of the BioBricks Public Agreement are meant to ameliorate the
threat of patent rights over BioBricks parts in an attempt to promote their open and free use.77
The main goal of this open strategy is to “accelerate the pace of innovation, collapse
development timelines and speed time-to-market of inventive synthetic biology-based solutions
while fostering the ethical use of the technology.”78 The contracts contain some terms that are
analogous to OSI open source terms of distribution.79 The BioBricks Public Agreement is
described as “a scalable contract among parties”—a contract “between one person who wants to
make a genetically encoded function free to use and someone who wants to use it freely.”80

fundamental building blocks of synthetic biology are freely available for open innovation; by creating community,
common values and shared standards; and by promoting biotechnology for all constructive interests.”).
74
Id.
75
FAQ, BIOBRICKS.ORG, http://biobricks.org/faq/ (last visited Feb. 11, 2012).
76
Id.
77
Id.
78
About the BioBricks Foundation, BIOBRICKS.ORG, http://biobricks.org/about-foundation/ (last visited Feb. 12,
2012).
79
Compare The BioBrick Contributor Agreement, BIOBRICKS.ORG, http://biobricks.org/wp-content/themes/bbf/bpasample.php (last visited Feb. 12, 2012) with Open Source Definition, supra note 64.
80
Frequently Asked Questions, BIOBRICKS.ORG, http://biobricks.org/bpa/faq/ (last visited Feb. 11, 2012).
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There are two distinct types of contract—one for the “Contributor” and one for the “User.”81
The Contributor is the person making the biological part available, while the User is the person
using the part that the contributor provided.82 The Contributor contract states that a Contributor
of a BioBricks part makes “an irrevocable promise not to assert any existing or future intellectual
property rights over the something against the other party to the contract.”83 Furthermore, the
Contributor of a BioBricks part must disclose the existence of any intellectual property rights to
the part held either by the Contributor or by a third party. 84 The User contract states that a User
promises to “provide attribution to the contributor, where requested, and to respect biological
safety practices and applicable laws.”85
Some commentators have noted that the BioBricks Public Agreement sets forth more
than the mere terms of a license intended to prevent disputes over ownership rights.86 Rather, the
terms of the BioBrick Agreement are “an initial effort to draft a legal constitution to guide the
beneficial development of the field of synthetic biology.”87
Importantly, the BioBricks Public Agreement does not include some provisions included
in the OSI terms of distribution.88 For example, the BioBricks Public Agreement does not
contain any provision requiring a grantback of any derived works. 89

As discussed in the

following section, the absence of some OSI terms of distribution will create significant
challenges to maintaining an open-source synthetic biology movement.
81

Id.
Id.
83
Id.
84
The BioBrick Contributor Agreement, BIOBRICKS.ORG, http://biobricks.org/wp-content/themes/bbf/bpasample.php (last visited Feb. 12, 2012) (section 4, Intellectual Property Rights).
85
Frequently asked Questions, supra note 80; The BioBrick User Agreement, BIOBRICKS.ORG,
http://biobricks.org/bpa/users/agreement/ (last visited Feb. 12, 2012).
86
Andrew Torrance, Synthesizing Law for Synthetic Biology, 11 MINN. J. L. SCI. & TECH. 629, 663 (2010).
87
Id.
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C. Challenges Maintaining the BioBricks Commons
There are several significant threats to the openness of the BioBrick commons. Three of
these challenges will be discussed in this section specifically. The first challenge is derivation:
getting contributors to donate derived work back to the BioBricks Foundation and not assert any
intellectual property rights. The second challenge is motivation: incentivizing individuals or
entities that currently hold patent rights of biological parts to donate them to the BioBricks
Foundation in the first place. The third challenge is the absence of an end product: the open
source synthetic biology community will not be able to realize the potential of novel medically
relevant inventions on its own. The first two challenges stem from the terms of the BioBricks
Public Agreement, while the third challenge is inherent in biomedically relevant research. Each
challenge will be considered in turn.
i. Derivation
One of the goals of the BioBricks Foundation open-source community is to foster the
creation of novel biological parts by derivation from the parts currently found in the registry. 90
But the absence of terms in the BioBricks Public Agreement that require all derived works to be
donated back to the BioBricks Foundation creates a challenge. Unless they are the inventor of
the biological part, a User would be barred from asserting any intellectual property rights over
any individual biological part once contributed to the BioBricks Foundation.91 But there is
nothing stopping a user from asserting intellectual property rights over a different biological part
that is derived from BioBrick parts. In other words, if a person has signed the BioBricks User
Agreement and, in using the BioBrick parts, creates a new part with a novel function, there is
90
91

See About the BioBricks Foundation, supra note 78.
35 U.S.C. § 102 (2006).
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nothing stopping that person from patenting that novel part and asserting intellectual property
rights over it. In fact, the User Agreement specifically states that there is no requirement to give
any novel materials or applications back to the foundation.92 The BioBricks Foundation makes
perfectly clear that “[n]ovel materials and applications produced using BPA-contributed parts
may be considered for protection via conventional property rights.”93 As a result, the BioBricks
User Agreement is fundamentally different from the traditional open source agreement, which
requires any derived works to be licensed back under the same terms as the original.94 Without a
reciprocal licensing mechanism in place to ensure that novel biological parts will continue to be
derived from past work of users, maintaining a cycle of innovation by participants in the
synthetic biology commons may be challenging.
ii. Motivation
A second problem, arguably equally as important as the first, is that there is no clear
reason for a person with intellectual property rights over a part to surrender those rights and
donate the part to the BioBricks Foundation. Arguably, the only motivation is to make a
philanthropic gesture.

Professor Andrew Torrance has noted that “it is not obvious what

incentives contributors would have to contribute their BioBricks, especially if they must
relinquish any intellectual property rights they may have in order to do so.”95
iii. End Product

92

Frequently Asked Questions, supra note 80.
Id.
94
Compare The BioBrick Contributor Agreement, BIOBRICKS.ORG, http://biobricks.org/wp-content/themes/bbf/bpasample.php (last visited Feb. 12, 2012) with Open Source Definition, supra note 64.
95
Torrance, supra note 86, at 660.
93
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There is a third problem that is unique to synthetic biology as applied to the field of
medicine—there is no immediately usable end product.96 Other open-source movements, such as
the open source software movement, were wildly successful partly due to the fact that a working
product resulted from the aggregate work of many individuals. For example, the Linux operating
system, developed over many years by thousands of people, is downloaded and used by anyone
in the world after all the effort has been put forth to make it.97 That is not always the case in the
world of biotechnology.98 If members of the BioBricks Foundation were to engineer a microbe
to be a medical therapy, the end product could not be immediately used because introduction of
the product requires lengthy, and extremely costly, clinical trials as a drug, biologic, or medical
device.99 It is likely that an entire community of BioBricks members would not have the
knowledge or resources available to undergo this task.
Thus, there are several problems to overcome in establishing a viable open source
synthetic biology movement. The first is getting people/corporations to make their derived
works, which may be very valuable, available for further use by the public free of charge. The
second is getting people/corporations with intellectual property rights to contribute parts. The
third, in the context of designing a medical therapy, is getting a synthetic biology product
through clinical trial so that it will actually be used to benefit the world.
The first two problems have been addressed in the context of other open-source
movements involving emerging technologies under the threat of patents stifling progress.100 In
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the context of those specific technologies, several different strategies have been devised to
maintain openness.

Parts IV and V will address three strategies that have been applied to other

technologies that can potentially be applied to maintaining open source synthetic biology. Each
of the following strategies has been evaluated previously in the context of a specific technology
and each has been successful in maintaining some degree of openness.101 Part IV will introduce
these previously proposed strategies. Part V will answer the question of whether any of the
proposed strategies would be applicable to a synthetic biology commons, and if so, whether it
would be successful. The three strategies to be evaluated are the Copyright Open-Source
approach, the HapMap License approach, and the BIOS patent approach.

IV. Previously Proposed Open Source Strategies
A. Copyright Open-Source Approach
Currently, copyright protection for sequences of DNA is not available.102

But if

sequences of DNA could be protected under Copyright Law, then it would be relatively
straightforward to implement open-source synthetic biology in an analogous fashion to opensource software.103 A license to use the DNA “work” would include provisions that require the
user to give back to the commons any derivative works.104 The General Public License (GPL)105
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that has been commonly used in open source software could be easily adapted to cover DNA106
and would have the same open source effect—novel sequences of DNA or novel combinations of
established sequences that have been derived from previous work covered by the GPL would
remain available to the public.
Several commentators have suggested that it is feasible for sequences of DNA to be
covered by copyright law.107 Some have even suggested that this approach could be used to
establish open source synthetic biology.108 These scholars have reasoned that DNA sequences
are very similar to computer software code because both involve a set of instructions that are
read, then executed, and any unique issues that might arise in the context of synthetic biology
could be absorbed with a relatively small incremental change to Copyright Law.109
For example, Dr. Christopher Holman makes the case that engineered DNA should be
protected by Copyright Law.110 He argues that “the major doctrinal leap occurred thirty years
ago when copyright protection was recognized for computer programs. In view of the close
analogy between software and engineered DNA, the further extension to encompass engineered
genetic sequences is a relatively modest incremental expansion.”111 Dr. Holman argues that
engineered sequences of DNA and computer code both are essentially sets of instructions that are
read and executed by hardware.112 For computer code, the hardware is the group of computer
components itself; for DNA sequences, the hardware is the group of proteins, carbohydrates, and
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fatty acids that make up a living cell.113 Further bolstering the Copyright argument, advances in
biotechnology have made possible a certain level of creativity in generating DNA sequences.114
This is important because the Supreme Court, in Feist Publications, Inc. v. Rural Telephone
Service Co. Inc.,115 established a minimum threshold for a work to be covered by Copyright
Law—the work must contain “a modicum of creativity.”116 This is a relatively low threshold
that could be easily met even with the current state of synthetic biology because the current state
of the technology allows for the creation of DNA sequences that are different—at least
modestly—from what exists in nature.117 Additionally, the Supreme Court has consistently
interpreted the Copyright Clause of the constitution broadly. 118 The term “writing” has not been
taken literally—photographs, art, motion pictures, and sounds have all been considered
“writings.”119 Thus, there is good reason to believe that a molecule of DNA could be considered
a “writing” and therefore could receive copyright protection.
Andrew Torrance makes a similar argument, but suggests that instead of only thinking
about DNA sequences as being analogous to computer software, DNA might even be thought of
as an actual form of computer software.120 This is especially true in the field of synthetic
biology, where in the future a heightened degree of programmability will allow for a potentially
limitless amount of creativity.121 This is seemingly equivalent to the freedom of a computer
programmer to create any form of program, constrained only by the computer language and
113
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hardware itself. Indeed, Torrance even notes that one of the “goals of synthetic biology is to
engineer cells and genes to become ever more like computers and computer software.” 122 If this
approach is assumed, then DNA is already covered by Copyright and no adaptation of law need
be made at all in order to protect sequences of DNA.

B. HapMap Licensing Approach
Some open-source movements use a contract-based license to create an information
commons in the realm of biotechnology and have been relatively successful.123

One in

particular, the International HapMap Project, was a joint public-private venture to map genetic
variation among the world’s human population.124 The stated goal of the HapMap project was to
“help researchers find genes associated with human disease and response to pharmaceuticals.”125
The HapMap Project originally created a data access policy that was meant to “avoid the filing of
intellectual property claims that would impede other users access to the data.”126 Due to the
success of open distribution, in 2004, approximately two years after the HapMap project had
started distributing haplotype data, the HapMap Consortium decided that its data access policy
was no longer required because enough data on human genetic variation was published that any
patents derived from HapMap data would be considered obvious.127 Since then, all access to
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HapMap haplotype data is freely accessible to anyone without having to sign a license
agreement.128
The data-access policy that the HapMap Consortium formerly used included a licensing
agreement that a user had to sign before gaining access to haplotype data.129 This mandatory
licensing agreement stated that “you will have to agree to a single condition—that you will not
restrict further use of the individual genotypes, i.e. take any action that would in any way restrict
the access of others to the data produced by the Project.”130 The licensing agreement also
prohibited distribution of data from the HapMap project to parties that had not accepted the
terms of the license.131 This provision addressed the possibility that a party who signed the
license could simply give the haplotype data to a third party who had not signed it and was not
bound by its terms.

C. The BiOS patent approach
Another past strategy to establish and maintain openness is a patent-based approach,
which the Biological Innovation for Open Society (BiOS) utilized.132 The BiOS initiative was
created “in response to inequities in food security, nutrition, health, natural resource management
and energy.”133 BiOS currently holds the intellectual property rights to several technologies
relevant to food production.134 For example, BiOS holds patents on several plant technologies,
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including plant-gene transfer methods, generation of plant-gene fusions, and methods for
genotyping genetically engineered plants.135 Because BiOS holds the patent rights associated
with those technologies, it can make those technologies freely available to anyone who wishes to
use them if they agree to the terms of the BiOS license.136 The mandatory license requires users
to “grant back any improvements in the core technology and to make such improvements freely
available to all others on the same terms that BiOS provided for the original core technology.”137
Some academics, such as Professor Robin Feldman, suggest that this grantback
requirement may implicate patent misuse.138 Patent misuse occurs when the patent holder
attempts to expand the physical or temporal scope of a patent monopoly beyond what was
originally granted in the patent.139 “To the extent that a patent holder uses its rights to restrict the
disposition of inventions not covered by the grant, the patent holder may be engaging in behavior
that extends the scope of the patent grant and thereby may be subject to a claim of misuse.”140
But by Professor Feldman’s reasoning, it is highly unlikely that BiOS would actually find itself
in court under a theory of patent misuse because the BiOS grantback requirement is not
inconsistent with patent policy and any anti-competitive effects are outweighed by the procompetitive benefits.141
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V. Application of Past Strategies to Synthetic Biology
In light of the previous open-source strategies described in Part IV, the question is
whether any of the copyright, license, or patent based approaches to maintaining openness would
work in the context of synthetic biology. The following section applies these previous strategies
to synthetic biology and assesses whether any of them can be used to maintain an open source
synthetic biology movement. Application of these strategies to the technology of synthetic
biology reveals that none of them are ideally suited to maintaining openness. The copyright
approach and patent based approach are especially unlikely to be useful because of recent federal
circuit decisions and prohibitive expense, respectively. While the license based approach can be
applied to synthetic biology, it has several flaws that must be overcome in order to sustain an
open source synthetic biology movement.

A. Copyright Availability For Open Source Synthetic Biology
The Copyright approach to open-source synthetic biology is not without problems
because the applicability of copyright to sequences of DNA is untested. While various scholars
have made several compelling arguments that DNA sequences should be covered by Copyright
Law, there is currently no indication that the U.S. Copyright Office or Congress would approve
the use of Copyright Law to protect DNA sequences.142 Also, Andrew Torrance, Sapna Kumar
and Arti Rai have pointed out that the Copyright approach may not work for DNA sequences that
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already exist in nature.143 Indeed, Copyright is intended to prevent verbatim copying of a
writing, whether it be in the form of computer software or DNA sequence. 144 Thus, no naturallyoccurring sequences of DNA could be protected under a Copyright.145 While designing novel
DNA sequences that do not exist in nature may become commonplace in the future with
synthetic biology, the current state of the technology largely involves previously existing genetic
code.146 For example, the vast majority of BioBrick parts made available in the registry are
sequences of DNA taken directly from naturally-occurring organisms.147
The Federal Circuit’s view on intellectual property rights of DNA poses another high
hurdle for DNA Copyright protection.148 While there is no direct indication that the Federal
Circuit would approve or disapprove the use of Copyright to protect sequences of DNA, there is
some indirect indication that it would not be receptive to Copyright protection for sequences of
DNA, even if the sequences were completely novel.149 The Association for Molecular Pathology
et al. v. United States Patent and Trademark Office et al. (Myriad gene patent case) offers some
insight into how the Federal Circuit views intellectual property rights surrounding sequences of
DNA.150 While patents and copyrights are distinct bodies of intellectual property law, the court’s
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reasoning in the gene patent cases may be an indication of future unwillingness to allow
Copyright protection for DNA.151
On July 29, 2011, a three-Judge panel in the Federal Circuit handed down three separate
opinions in the controversial Myriad gene patent case.152 The original decision on appeal,
authored by Judge Sweet from the Southern District of New York, held that a composition of
isolated genomic DNA was not patentable subject matter.153 Judge Sweet seized the idea that
DNA is a carrier of information and that this property gives it utility.154 Any isolated DNA
containing the same sequence information of native DNA is therefore a product of nature and
unpatentable.

155

Two out of the three judges on the Federal Circuit panel, completely rejected

Judge Sweet’s reasoning.156

Judge Lourie held that focusing on the “information content

contained in . . . DNA’s nucleotide sequence” ignores the distinctive characteristics that isolated
DNA molecules have when compared to what exists in nature.157 Judge Lourie further stated
that when determining patent eligibility of DNA, the “informational content is irrelevant.”158
Judge Moore concurred with Judge Lourie on the issue of patent eligibility of isolated genomic
DNA sequences, but wrote separately to emphasize the differences in utility of isolated DNA
when compared to native DNA.159
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If the majority of the Federal Circuit panel had agreed with Judge Sweet and emphasized
the information carrying qualities of DNA, a parallel argument could be made that, while not
patentable, sequences of DNA could be protected by copyright law. If the informational aspect
of a molecule of DNA was emphasized, then one could reasonably argue that the genetic
information is simply read and executed by other cellular machinery in an analogous fashion to a
computer reading and executing software instructions.160 Thus, if courts emphasize the
informational aspect of DNA, then there would exist some judicial reasoning in support of the
conclusions of Hollman and Torrance that Copyright should be applicable to sequences of DNA,
much like Copyright is applicable to computer software.161
Since the majority of panel judges rejected viewing DNA as, first and foremost, a carrier
of information, the arguments for the copyright protection of DNA sequences would not find
support in the reasoning of the Federal Circuit. Furthermore, with the Federal Circuit’s decision
in the Myriad gene patent case, patents are clearly available for protection of sequences of
DNA.162 As Kumar and Rai have noted, “courts and Congress might be reluctant to layer on an
entirely new kind of property right, for fear that such rights would hurt rather than help
innovation.”163 Thus, despite the sound arguments for why DNA should be protected under
copyright law, it is unlikely that the Federal Circuit would actually support its use in that context.
The intellectual property rights available to sequences of DNA may change in the future.
The Ass’n for Molecular Pathology et al. appealed the Federal Circuit’s Myriad gene patent case
decision to the Supreme Court, which remanded the case to the Federal Circuit for consideration
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in light of the Supreme Court’s decision in Mayo Collaborative Services v. Prometheus
Laboratories.164 If the Supreme Court eventually takes the case and upholds the Federal Circuit
majority, then the applicability of copyright protection to sequences of DNA will remain
unlikely.

But if the Supreme Court were to agree with Judge Sweet, and emphasize the

information-carrying properties of DNA sequences, it could effectively close the door on
genomic DNA patents and open the door to genomic DNA copyrights.

B. Application of HapMap Strategy to the BioBrick Public Agreement
Application of a HapMap license approach to maintaining an open source synthetic
biology movement is possible, but brings with it issues associated with third-parties not in privity
of contract and issues of enforcement. The HapMap Licensing terms, which were relatively
successful in establishing the open use of haplotype data, have some similarities to the current
BioBricks Public Agreement.165 Both agreements contain terms that prohibit placing restrictions
on the information/part that has been made available.166 Importantly, this strategy does not
require any intellectual property right to bind the signing party to the terms of the license.167
Kumar and Rai note that “this contractual alternative does not require an underlying property
right.

Instead, the contract simply imposes conditions as part of the price of access.”168

Furthermore, the online nature of a license-based strategy requires that the agreed upon webbased contract be enforceable. Donna Gitter has noted that “courts generally enforce clickwrap
164
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agreements provided the licensee ‘receive[s] notice of the license terms before buying or using’ .
. . ‘and has the ability to return . . . if he does not agree with the terms . . . ’”169 Since the
HapMap user agreement was deemed to fulfilled these threshold requirements for enforceability,
the similar click-wrap nature of the BioBricks agreement would likely fulfill these threshold
requirements as well. There are, however, several issues that still must be overcome.
i. Third-Party Problems
Third parties not in privity of contract who gain access to BioBricks parts, however, will
create problems that must be overcome. Commentators have pointed out that a licensing
agreement would not prevent third parties, who have gained access without signing, from
violating its terms.170 Gitter points out that the HapMap license “does not bind third parties who
obtain and use HapMap data without downloading it from the HapMap website and who
therefore are not in privity of contract . . .”171 A similar problem exists in the case of the
BioBricks Public Agreement; any third party that obtains a BioBrick part without agreeing to the
license would not be bound by its terms.172 The HapMap approach to overcoming this problem
was to include terms in the user agreement that specifically prohibited dissemination of HapMap
data to parties that have not signed an agreement.173 Kumar and Rai suggest that this indicates
one of the difficulties when using contract law to maintain openness: “the comparative weakness
of the contractual restraints paradoxically requires extremely broad restrictions on
dissemination.”174 A similar contradiction would exist in the context of the synthetic biology
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commons: the openness of the BioBricks parts could only be protected from third parties by
severely restricting the openness of the BioBricks parts.
The BioBricks Foundation has not, however, implemented this type of third-party
restriction.175 In contrast, the BioBricks Foundation’s ethos of openness suggests that it would
actually want to encourage the free distribution of BioBricks parts to third parties in hopes of a
third-party eventually making a donation back to the foundation.176 Thus, any third-party issues
that existed in the context of the HapMap project will likely be amplified greatly in the context
of the BioBrick Foundation, due to the absence of dissemination restrictions.
ii. Enforcement Problems
In addition to the problems associated with third parties violating the terms of a license,
there may also be enforcement problems even with parties who have agreed to the license terms.
For example, a party may agree to a license that relinquishes any intellectual property rights, but
that party may later ignore the provision and file for a patent anyway. Under this circumstance,
there is no reason to believe that the patent would be void. As Professor David Opderbeck has
noted, “[n]othing in the Patent Act would suggest that a patent could be invalidated because
some of the underlying data was derived from a database in violation of the database’s terms of
use. Thus it is unlikely that the [license] provides any meaningful remedy once a patent has been
filed.”177 In terms of the BioBrick Public Agreement, an individual could fail to disclose the
existence of a pending patent on a biological part, but the resulting patent would not be
invalidated due to this violation.178 Thus, users may disregard the terms of the BioBricks Public
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Agreement, which are meant to maintain openness, without any real recourse for the BioBricks
Foundation.179
There are further issues that arise if the Foundation decided to enforce the terms of the
BioBricks Agreement in court. Gitter notes that bringing suit against all parties who violate the
user agreement would “create a significant financial and administrative strain upon the nonprofit
research group, which must focus its efforts on pursuing research as opposed to enforcing its data
access policy.”180 This certainly applies to the BioBrick Foundation, which is also a non-profit
organization and has limited financial resources. Additionally, the area of biotechnology is very
much an international enterprise, and there may be no remedy against people who violate the
terms of the BioBricks Agreement in other countries.181 As Gitter states, “[i]f the user happens to
be located in a nation that does not enforce clickwrap licenses, then that user might not face legal
liability for violating the . . . license.”182

C. Application of BIOS Approach to BioBricks
There are several problems with attempting to maintain the synthetic biology commons
using a patent-based strategy. First, for this strategy to work, BioBricks would have to hold
either a few broad foundational patents or a patent on each individual part in the collection. Both
of these options pose problems.
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Unlike the BiOS Initiative, currently the BioBricks Foundation does not hold the patent
rights to any broad foundational patents.183 While a few broad foundational patents might be
successfully used to maintain a commons, the difficulty with this approach would be to “identify
an area of inventive territory that was quite broad but nonetheless not suggested either by prior
broad patents or by information already in the public domain.”184 Considering the existence of
several issued broad foundational patents, it is not likely that the BioBricks Foundation would be
successful if it were to proceed with this approach.
The alternative is to obtain a very narrow patent on each BioBricks part currently in the
registry. This strategy would not only require the BioBricks Foundation to patent each part for
which it is the inventor, it would also require each individual “inventor” who donates his or her
part to the Foundation to obtain a patent as well. This is not practically possible. Obtaining a
patent on a sequence of DNA, or any other structure or method, could cost tens of thousands of
dollars each.185 The BioBrick registry currently holds thousands of BioBrick parts.186 Thus, the
aggregate cost of maintaining a synthetic biology commons by patenting each individual part
would easily be in the tens of millions of dollars. This is a prohibitively large amount even for a
large for-profit corporation and simply is not possible for the BioBrick Foundation.
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VI. A standard setting organization (SSO) strategy for establishing, maintaining, and using the
end products of the synthetic biology commons
Part IV of this Comment introduced various strategies that have been used in the past for
maintaining openness in different technological areas.187 Part V then applied those strategies to
the technology of synthetic biology, concluding that a copyright- or patent-based approach is not
possible and a license approach is less than ideal.188 Each of the previous strategies discussed to
this point only address the problem of getting derived works of synthetic biology donated back to
an open source community. The problem of motivating patent holders to donate biological parts
in the first place and the problem of getting biomedical end products into the clinic have not been
addressed. The following subsections lay out a novel strategy that may be able to tackle
problems of maintaining openness while at the same time incentivizing donations and creating
opportunities for realizing biomedical breakthroughs. This strategy involves establishing a
synthetic biology standard setting organization (SSO).

A. Standard Setting Organizations (SSO)
An SSO, also known as standard setting consortia, can consist of “anything from a loose,
unincorporated affiliation of companies, to an incorporated entity with offices, marketing,
technical and administrative staff and a multi-million dollar budget.”189 The goal of this type of
organization is to set standards that are widely adopted throughout an industry in order to enable
innovation of a business-service or product.190 The importance of standard setting cannot be
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overstated.

Standards are found everywhere in our daily life.

The classic example is an

electrical plug and socket191—people in the United States can go to any store in the country and
purchase any tool or device that requires power and be confident that they will be able to go
home and the plug will fit. Both the plug on the device and the electrical socket in the home are
guaranteed to work together because a standard has been adopted. Furthermore, “[o]rdinary
products like printer cartridges and tires come in standardized sizes and specifications, which
fosters choice and competition in the supply of replacement parts.”192 Thus, standards have the
beneficial effects of promoting efficiency of innovation as well as competition in a marketplace.
Standards can be broadly classified into three groups: de facto standards, private
standards, and government standards.193 De facto standards arise naturally in a market place
when users adopt a standard to the exclusion of any competition.194 Government standards, in
contrast, are promoted and enforced by a government entity—for example, the U.S. government
selected a uniform standard for High Definition television in the 1990’s.195 Finally, private
standards are adopted voluntarily by members of an industry, usually after the formation of a
private SSO.196 Joining a private SSO is completely voluntary, “some flourish, while others
enjoy only middling success, and some fail to gain traction at all.”197
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At the core of an SSO is the establishment of policies to deal with intellectual property
rights, namely patents.198 To accomplish this, each SSO establishes a set of rules addressing the
intellectual property rights of members who have joined.199 Two particularly important issues
covered in the SSO rules are “whether and when patent claims must be disclosed” and the
reasonable and nondiscriminatory (“RAND”) terms by which a member will license patent rights
to other members.200 The RAND terms of a private SSO could possibly be designed to address
the problems of maintaining open-source synthetic biology.

B. A Standard Setting Organization Could Address the Problems of Maintaining Open Source
Synthetic Biology
The establishment of a private standard setting organization might address the problem of
incentivizing donation of patented biological parts by creating a medium through which the part
could be used by an open source community while at the same time protecting the intellectual
property rights of the donor. An SSO might address issues involved with using a license to get
derivative biological parts donated back to an open source community. Finally, an SSO could
foster collaboration between an open source synthetic biology community and private entities in
order to introduce synthetic biology products into the clinic.
i. Motivating Donation of Biological Parts
An SSO could overcome the problem of motivation by generating future value of a
patented biological part, while at the same time protecting the intellectual property rights of the
donor. In some situations donation of parts might be made freely. There is evidence that entities

198

Id.
Id.
200
Id.
199

35

holding patent rights over certain technologies would be willing to allow an open source
community to use those technologies free of charge. For example, IBM has pledged several
hundred patents to the open source community in order to foster innovation. 201
IBM is committed to promoting innovation for the benefit of our customers and for
the overall growth and advancement of the information technology field. IBM takes
many actions to promote innovation. Today, we are announcing a new innovation
initiative. We are pledging the free use of 500 of our U.S. patents, as well as all
counterparts of these patents issued in other countries, in the development,
distribution, and use of open source software. We believe that the open source
community has been at the forefront of innovation and we are taking this action to
encourage additional innovation for open platforms.202
IBM is likely willing to donate patents because those patents are more valuable being used by the
masses of an open source community than languishing undeveloped by the company. Future
value from the use of patented technology by a community can be generated by technological
advances that IBM can later capitalize on. There is no reason to think that this perceived future
value is limited to the context of software. It is entirely possible that biotechnology companies
and universities, which hold patents on foundational technologies relevant to synthetic biology,
would similarly value work done by the open source community of the BioBricks Foundation.
But getting patent holders to donate the presently valuable intellectual property rights to
an open source community will be more challenging. This is despite the fact that an open-source
community can also generate future value from technology patents no matter what the present
value is.203 Patent holders may be hesitant to donate their biological parts to the BioBricks
Foundation via the standard BioBricks Public Agreement because it would prevent enforcement
of any rights against users. The terms of the Public Agreement create a risk for an entity that has
201
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invested large sums of money in obtaining a patent over valuable sequences of DNA because a
competitor could theoretically sign its own BioBrick Public Agreement and then be able to
infringe patent rights with impunity. By donating a valuable biological part to the BioBrick
Foundation, a patent holder might inadvertently give up rights to a direct competitor.
This problem could possibly be overcome by a direct agreement between the BioBrick
Foundation and a patent holder, in which it is agreed to allow the use of patented technology by
members of the BioBrick Foundation, without actually signing the Contributor Agreement. This,
however, leaves open the possibility that the patent holder could decide to assert intellectual
property rights at a later date, stopping all future innovation with the part. No member of the
BioBrick Foundation would want to invest time developing a technology only to be told to stop
at some future date.
The establishment of a private standard setting organization would create a medium
through which the patented biological part could be given to BioBrick members while at the
same time protecting the intellectual property rights of the donor.

The private SSO would

include a unique provision to achieve this end. The SSO contract would contain an ex-ante
RAND term that creates a sliding scale based on the non-profit or for-profit nature of the entity
using the patented material.

For the non-profit organization, the reasonable and

nondiscriminatory license fee would be zero. For all other organizations joining the privateSSO, the license terms would follow the fair market value of the patent rights. Using RAND
terms of this nature will motivate patent holders of biological parts to donate them to an open
source community because future value will be generated on the part, and competitors would not
have the opportunity to exploit a donation.
ii. An SSO Addresses Issues of Enforceability Involved with a Licensing Agreement
37

As discussed in Section V above, one of the problems with using a contract licensing
approach to maintaining openness in the BioBricks Foundation is that the terms can be violated
by a party without any real recourse.204 For example, a donor of a biological part could make a
promise not to assert any patent rights over a donated part, but then later demand that the part not
be used. To remedy this, donation of biological parts under the umbrella of an SSO would make
it perfectly clear that the agreement is not simply an agreement among parties to use the patented
material, but rather the adoption of a standard part in which time and money will be invested.
This clear establishment that a standard is being adopted will bring with it several aspects of
protection that exist in common law.
There is clear case law indicating that, when a patent holder induces another party to
adopt a standard, the patent holder cannot arbitrarily enforce his or her rights.205 One legal
theory is that of equitable estoppel. In Stambler v. Diebold, Inc., the plaintiff allowed the
American National Standards Institute (ANSI) to adopt a technology relating to ATM machines
as the standard.206 The court held that there was evidence of “misleading conduct on the part of
the plaintiff that may have led the defendant to conclude that plaintiff did not intend to enforce
his patent” and further that the conduct was intentional.207 The court used a theory of estoppel to
deny the plaintiff the right to enforce the patent.208 The court reasoned that the plaintiff had a
duty to speak out rather than allow the industry to adopt the standard.209
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Furthermore, the Federal Circuit Court of Appeals has articulated a three-part test to
determine whether a party may use equitable estoppel to bar a patent infringement claim.210 The
court put forward three elements required to invoke equitable estoppel.211 First, the patent holder
must lead the infringer, by misleading conduct, to reasonably infer that no property rights will be
asserted.212

Types of misleading conduct include “specific statements, action, inaction, or

silence where there was an obligation to speak.”213 Second, the infringer must have relied on the
misleading conduct of the patent holder.214 Third, the infringer will be materially prejudiced by
allowing proceedings to continue.215
Applying this three-part test would most likely result in equitable estoppel in the context
of a biological part donated to the BioBricks Foundation under an SSO. If a BioBricks part
Contributor tried to revoke the license of a patent after donating a biological part, all the
elements of equitable estoppel would be fulfilled. First, the BioBricks Foundation would have
reasonably inferred that the Contributor did not enforce the patent because of the acceptance of
the contributor’s donation. Second, BioBricks would have relied on that agreement by depositing
the DNA part into the registry. Third, the BioBrick Foundation would be materially prejudiced
by enforcement because the foundation would have to, at minimum, spend the time and money
removing the DNA part from the database.
An alternative legal theory preventing the assertion of patent rights over an adopted
standard is that of an implied license.216 Under this theory, future use of the donated biological
part would not be protected, but damages could not be awarded for use up to the point of
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notice.217

In AMP Incorporated v. The United States, AMP entered into a contract with the

government to furnish “60 experimental models of [a] wire splicing tool.”218 The contract
granted the government “an irrevocable, non-exclusive, nontransferable and royalty-free” license
to use the tool.219 After AMP had shipped the items, it discovered that its patent on the tool had
been infringing another company’s patent.220 AMP purchased the rights to the other companies
patent and then tried to revoke the original license it granted the government.221 The court held
that an implied license existed between AMP and the government, even though the government
would have been infringing the third party’s patent.222 The court reasoned that a license cannot
be negated if there is no change in the structure of the invention.223
iii. Enforcing SSO Terms and Bringing Synthetic Biology to the Clinic
In the context of a standard setting organization, a scenario is created where proprietary
entities and open source communities would have an aligned interest in the standard that gets
adopted. The patent holder benefits from an increased value of an adopted standard; the parties
using the patented technology would benefit from enhanced ability to innovate and collaborate
through use of the standard. This alignment of interest could significantly benefit the BioBricks
Foundation because the financial resources of a for-profit corporation might be used to prevent
any individual member of the SSO from “gaming” the system. 224 For example, an SSO member
that promotes the use of a patented technology, but later tries to enforce patent rights on

217

Id.
Id.
219
Id.
220
Id.
221
AMP Inc., 389 F.2d at 448.
222
Id.
223
Id.
224
See Lemly, supra note 193.
218

40

unreasonable terms, could be sued under one of the legal theories described above.225
Unfortunately, this would require financial resources that the BioBick Foundation does not have
on its own. If, however, the interests of the other SSO members were aligned with that of the
BioBrick Foundation, then a party with money to spend could be present, and would protect the
interest of the BioBrick Foundation incidentally with its own self-interest. Thus, the legal
recourse existing, but practically not possible to use, becomes available to the BioBrick
Foundation in the context of an SSO.
Also, the aligned interests of the BioBrick Foundation with the for-profit members of the
SSO make it possible to address a problem to establishing a synthetic biology commons that no
other previously proposed strategy could—that is, get finished, medically relevant, products of
BioBrick members out of the lab and into the clinic. For profit biotechnology companies have
the resources and expertise available to undergo the arduous process of a clinical trial. Also,
since clinical trials last many years, the single entity of a corporation could stay focused on
seeing the process through, without burdening any individual person. These are things that a
synthetic biology commons could not achieve by its very nature, with many individuals investing
little time and money and producing something big with their aggregate work. Thus, with the
alignment of interests, the novel biological parts made by BioBrick members could be used
freely by all for-profit members of the SSO. These novel biological parts could then be used to
derive therapies, which can be patented, incentivizing investment into clinical trials. To keep the
cycle of innovation going, the for-profit patented technologies could be adopted as standards and
used further by BioBricks members under the same SSO terms.

225

See A.C. Aukerman Co. v. R.L. Chaides Construction co., 960 F.2d 1020 (Fed. Cir. 1992); AMP Inc. v. U.S., 389
F.2d 448 (Ct. Cl. 1968).

41

Conclusion
The emerging technology of synthetic biology promises to have a huge impact on
industry and medicine.226 With that in mind, efforts should be made to promote the development
of the technology in a way that maximizes the speed of innovation.

In the world of

biotechnology, where patents dominate,227 an open source approach to synthetic biology may be
a good way to drive the technology forward and avoid potential stifling effects of intellectual
property rights. This Comment has reviewed some problems associated with an open-source
approach to synthetic biology and various strategies used in the context of other technologies for
maintaining openness. This Comment argues that a patent or copyright approach for maintaining
openness is not possible and that a license approach is less than ideal. This Comment proposes a
novel SSO approach that could not only maintain openness, but also motivate donation of
synthetic biology parts and help bring biomedical advances closer to clinical trials. The stated
goal of the BioBrick Foundation is to “accelerate the pace of innovation, collapse development
timelines and speed time-to-market of inventive synthetic biology-based solutions.”228 Private
standard setting organizations have achieved these same ends with various other technologies.229
Thus, even though the BioBrick Foundation strategy for advancing synthetic biology involves
largely open source principles, the goals of the Foundation may be better advanced by the
establishment of a formal private standard setting organization. In a world where sequences of
DNA are deemed patentable subject matter and intellectual property rights over foundational
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technologies threaten to stifle progress, creative thinking is necessary in order to advance
synthetic biology, and unlock the vast potential it has to benefit the world.
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